Us approves anti malarial drug to treat coronavirus trump

You're referring to the recent news about the anti-malarial drug hydroxychloroquine (HCQ) and its potential use in treating COVID-19.

On March 19, 2020, President Trump announced that the FDA had approved the use of hydroxychloroquine (HCQ) to treat COVID-19, citing anecdotal evidence and a small study that suggested it might be effective in reducing the severity of the disease.

However, it's important to note that the FDA did not actually approve HCQ as a treatment for COVID-19. Instead, the agency issued an Emergency Use Authorization (EUA) for HCQ, which allows it to be used in certain circumstances, such as in hospitalized patients who are critically ill with COVID-19.

The EUA was granted based on the results of a small study conducted by the National Institutes of Health (NIH), which found that HCQ may be effective in reducing the severity of COVID-19 in hospitalized patients. However, the study had several limitations, including a small sample size and a lack of a control group.

Since then, numerous studies have been conducted to evaluate the effectiveness of HCQ in treating COVID-19, and the results have been mixed. Some studies have suggested that HCQ may be effective in reducing the severity of the disease, while others have found no benefit or even suggested that it may be harmful.

The World Health Organization (WHO) has also issued guidance on the use of HCQ in treating COVID-19, stating that it is not recommended for use outside of clinical trials due to the lack of evidence supporting its effectiveness.

In summary, while the FDA did not approve HCQ as a treatment for COVID-19, it did issue an EUA allowing it to be used in certain circumstances. However, the evidence supporting its effectiveness is limited, and the WHO has recommended against its use outside of clinical trials.